Journal of Diabetes最新文献

{"title":"Sodium-Glucose Cotransporter 2 Inhibitors for Metabolic Dysfunction-Associated Steatohepatitis","authors":"Jiayang Lin,&nbsp;Yan Huang,&nbsp;Bingyan Xu,&nbsp;Chensihan Huang,&nbsp;Fei Teng,&nbsp;Youwen Yuan,&nbsp;Jinhua Zhang,&nbsp;Huijie Zhang","doi":"10.1111/1753-0407.70206","DOIUrl":"10.1111/1753-0407.70206","url":null,"abstract":"<p>MASH denotes metabolic dysfunction-associated steatohepatitis. MASH improvement was defined as a decrease in the non-alcoholic fatty liver disease activity score (NAS) of ≥ 2 points or NAS ≤ 3 at week 48 after treatment, with no worsening of fibrosis (i.e., no increase in fibrosis stage). MASH resolution was defined as a hepatocellular ballooning score of 0 and a lobular inflammation score of 0 or 1 at week 48, with no worsening of fibrosis. Fibrosis improvement was defined as a reduction in fibrosis of ≥ 1 stage at week 48, with no worsening of MASH (i.e., no increase in steatosis, ballooning, or inflammation scores).\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 3","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12966765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147369040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Interaction Between Mitophagy Dysregulation and the Diabetic Bladder Microenvironment","authors":"Shi Li,&nbsp;Zongyao Fan,&nbsp;Zheng Duan,&nbsp;Jun Xue,&nbsp;Zhongqing Wei","doi":"10.1111/1753-0407.70199","DOIUrl":"10.1111/1753-0407.70199","url":null,"abstract":"<p>Diabetic bladder dysfunction (DBD) is a prevalent and multifactorial urological complication of diabetes, with pathogenesis driven by complex interactions between hyperglycemia-induced oxidative stress, mitochondrial dysfunction, and bladder microenvironment dysregulation. Mitophagy, a selective autophagic process critical for mitochondrial quality control, has been linked to various metabolic diseases, but its precise role and the bidirectional interactions with the diabetic bladder microenvironment remain underexplored. This review outlines a novel, self-reinforcing feedback loop central to DBD progression. In this cycle, hyperglycemia impairs both the PINK1/Parkin-mediated mitophagy pathway and ubiquitin-independent pathways like FUNDC1 under hypoxic conditions, leading to the accumulation of damaged mitochondria. Mitochondrial dysfunction then exacerbates microenvironmental damage through excessive mitochondrial reactive oxygen species (mtROS) production, release of damage-associated molecular patterns (DAMPs), and activation of the NLRP3 inflammasome, which further drives inflammation, fibrosis, and extracellular matrix (ECM) remodeling. This aggravated microenvironment inhibits mitophagy, thereby accelerating the pathogenic cycle. Beyond elucidating this loop, this review suggests that targeting it offers a promising therapeutic strategy. A breakthrough in DBD treatment may necessitate a combined approach that both restores mitophagy and modulates the microenvironment. Additionally, this study critically reviews several promising, yet underexplored, interventions, including pharmacological mitophagy activation with urolithin A, NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome inhibition via MCC950, and advanced techniques like nanoparticle-mediated PINK1 mRNA delivery and CRISPR/Cas9-based Parkin gene editing. Future research should incorporate spatial transcriptomics to resolve cellular heterogeneity, develop targeted nanodelivery systems, and establish mechanism-driven, highly specific combination therapies to enable precision medicine for DBD.</p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 3","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12966769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147369034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond GLP-1","authors":"Zachary Bloomgarden","doi":"10.1111/1753-0407.70204","DOIUrl":"10.1111/1753-0407.70204","url":null,"abstract":"<p>The prevalence of obesity in the United States increased from 19.3% of the adult population in 1990 to 42.5% in 2022, with a forecasted increase to 46.9% in 2035 [<span>1</span>]; globally the trends appear similar [<span>2</span>]. The glucagon-like peptide-1 receptor agonists (GLP1-RAs) have shown remarkable success in treating overweight and obesity, with 12% of adults in the United States said to have at least temporarily received one of these agents [<span>3</span>]. However, a number of issues should be considered in GLP-1RA use. Not all treated individuals have the desired degree of weight loss; this is particularly an issue for people with type 2 diabetes, for whom the degree of weight loss is less than that among people not having diabetes [<span>4</span>]. Gastrointestinal intolerance prevents a sizable number of people from using these agents or necessitates their use in lower doses. We have reviewed the question as to whether weight loss-associated decrease in muscle mass may lead to clinical sarcopenia, in turn associated with frailty and susceptibility to a variety of adverse consequences [<span>5</span>]. It is likely that these considerations are relevant to important subsets of treated individuals as we further extend weight control agents to address more chronic illnesses. The development of novel approaches to attain weight loss, with greater gastrointestinal tolerability, and without reduction in muscle mass should then be seen as a priority. The approaches being evaluated span a variety of different mechanisms. Their use will almost certainly be developed in conjunction with GLP-1RAs, potentially allowing more tolerable dosing and a greater degree of weight loss in.</p><p>Over the coming issues of the Journal of Diabetes, we will review some potential adjunctive agents that may find efficacy in combination with the GLP-1RA in an effort to stimulate discussion of these approaches (Figure 1). We look forward to contributions to the Journal addressing these approaches.</p><p>The author has nothing to report.</p><p>The author declares no conflicts of interest.</p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 2","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12961913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147353062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Predictive Value of Hemoglobin Glycation Index and Clonal Hematopoiesis of Indeterminate Potential Among AMI Patients—A Prospective Registry Study","authors":"Linghan Xue,&nbsp;Wenhao Dong,&nbsp;Jiannan Li,&nbsp;Runzhen Chen,&nbsp;Nan Li,&nbsp;Chen Liu,&nbsp;Peng Zhou,&nbsp;Yi Chen,&nbsp;Li Song,&nbsp;Xiaoxiao Zhao,&nbsp;Hongbing Yan,&nbsp;Hanjun Zhao","doi":"10.1111/1753-0407.70195","DOIUrl":"10.1111/1753-0407.70195","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The objective of this research is to explore the combined effect of hemoglobin glycation index (HGI) and clonal hematopoiesis of indeterminate potential (CHIP) on all-cause mortality among patients diagnosed with acute myocardial infarction (AMI).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The presence of CHIP in peripheral blood cells was detected using deep targeted sequencing. AMI patients were divided into groups based on the median value of HGI and assessed for the effect of CHIP on all-cause mortality using multivariable Cox regression and Kaplan–Meier analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Multivariable Cox regression indicated that among patients with HGI above the median value, CHIP carriers exhibited a significantly higher all-cause mortality (any CHIP, adjusted HR: 2.06 95% CI: 1.10–3.85; <i>p</i> = 0.023), with analysis of specific mutations identifying particularly high risks for TET2 (adjusted HR: 3.72, 95% CI: 1.37–10.09; <i>p</i> = 0.010) and TET2/ASXL1 co-mutations (adjusted HR: 2.61, 95% CI: 1.08–6.30; <i>p</i> = 0.033). Kaplan–Meier analysis in the high-HGI group confirmed that carriers of any CHIP (<i>p</i> &lt; 0.001) and common CHIP (<i>p</i> = 0.019) had a higher risk of mortality than noncarriers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our study reveals that HGI significantly modifies CHIP-related all-cause mortality risk, which provides a way for refined risk stratification in patients with AMI.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 2","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12909099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146206157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insulin or Dapagliflozin Potentially Improves Microcirculatory Dysfunction or INOCA Related to Culprit Vessels in Diabetic Patients With STEMI After DCB Therapy During Long-Term Follow-Up","authors":"Wei You,&nbsp;Xianglian Ma,&nbsp;Yan Xu,&nbsp;Xiaoping Jin,&nbsp;Wenxing Mao,&nbsp;Meili Ji,&nbsp;Tianyi Huang,&nbsp;Peina Meng,&nbsp;Tian Xu,&nbsp;Yifei Wang,&nbsp;Tianlei Zhang,&nbsp;Zhiming Wu,&nbsp;Fei Ye,&nbsp;Xiangqi Wu","doi":"10.1111/1753-0407.70197","DOIUrl":"10.1111/1753-0407.70197","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study aims to investigate the relationship between risk factors and IRA-related microcirculatory dysfunction, as well as its pharmacological intervention in the context of STEMI treatment using DCB over a two-year period, especially in those with diabetes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective study enrolled 297 consecutive eligible patients diagnosed with STEMI who received DCB treatment from two centers. Clinical and procedure-related parameters were collected. AMR and adverse cardiac events were recorded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Immediately after DCB therapy, IRA-AMR in non-diabetes or good-glycemic control group was significantly smaller than that in diabetes or poor-glycemic control group (<i>p</i> &lt; 0.01). Compared with insulin or dapagliflozin group, IRA-AMR in non-insulin or non-dapagliflozin group was significantly higher (<i>p</i> &lt; 0.01). Univariate and multivariate Cox regression indicated that diabetes was a significant predictor of IRA-INOCA after a 2-year follow-up (<i>p</i> &lt; 0.05). Furthermore, administration of anti-diabetic medications and poor glycemic control post DCB treatment surfaced as significant predictors (<i>p</i> &lt; 0.01). Diabetic patients exhibited a significantly higher incidence of cardiac death along with IRA-INOCA complications compared to their non-diabetic counterparts (<i>p</i> &lt; 0.01). IRA-AMR in diabetic individuals immediately following DCB treatment was significantly lower than those in individuals who experienced inadequate-glycemic management and were readmitted due to IRA-INOCA complications (<i>p</i> &lt; 0.01). The incidence of IRA-INOCA in good-glycemic control, insulin, or dapagliflozin group was significantly lower compared with that in poor-glycemic control, non-insulin, or non-dapagliflozin group (<i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This finding highlights the importance of managing glycemic control, especially using insulin or dapagliflozin, in diabetic patients with STEMI after DCB treatment. Such measures may improve long-term cardiovascular outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 2","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12910173/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146206096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delphi Consensus on the Use of Fenofibrate as Systemic Therapy for the Prevention of Diabetic Retinopathy Progression","authors":"Richard C. O'Brien,&nbsp;Khalifa Abdallah,&nbsp;Xuehong Dong,&nbsp;Mohamed Hassanein,&nbsp;Qiuhe Ji,&nbsp;Sakir Ozgur Keskek,&nbsp;Patricio Lopez-Jaramillo,&nbsp;Roopa Mehta,&nbsp;Hussein Raef,&nbsp;Kevin Tan","doi":"10.1111/1753-0407.70193","DOIUrl":"10.1111/1753-0407.70193","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Diabetic retinopathy remains a leading cause of preventable blindness worldwide, yet screening and management practices vary widely. Evidence suggests that systemic therapies, including fenofibrate, may slow diabetic retinopathy progression, but their use is inconsistent across clinical settings. This study aimed to establish an evidence-informed consensus among endocrinology experts on the screening, diagnosis, and treatment of diabetic retinopathy, with a particular focus on recommendations for the use of systemic therapy to prevent disease progression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A modified three-round Delphi process was conducted with 19 endocrinology experts from diverse geographic regions. A core panel of 10 experts and an extended panel of 9 reviewed and rated 19 evidence-based statements. Consensus was defined as &gt; 75% agreement.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>All 19 statements achieved consensus, with 14 receiving &gt; 80% agreement. The panel endorsed frequent diabetic retinopathy screening based on diabetes type and risk level, early initiation of fenofibrate in patients with mild to moderate non-proliferative diabetic retinopathy, and continued therapy to sustain retinal protection. Fenofibrate was recognized for its pleiotropic effects, and the experts agreed that the transient rise in serum creatinine with fenofibrate is not indicative of renal damage and should not prompt discontinuation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This consensus highlights the need for multidisciplinary care, coordinated pathways, and patient education in diabetic retinopathy care. It also offers unified, evidence-informed recommendations for endocrinologists for the early initiation of fenofibrate to reduce diabetic retinopathy progression. While further studies are needed, these findings offer a practical framework for improving diabetic retinopathy management globally.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 2","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12895469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146163199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood Glucose and Hemoglobin A1c Trends Pre-, During, and Post-COVID-19 Pandemic in an Urban Population","authors":"Wayne Shih,&nbsp;Roham Hadidchi,&nbsp;Ekram Ali,&nbsp;Sonya Henry,&nbsp;Tim Q. Duong","doi":"10.1111/1753-0407.70190","DOIUrl":"10.1111/1753-0407.70190","url":null,"abstract":"&lt;p&gt;Blood glucose level (BGL) and hemoglobin A1c are key indicators of metabolic health and predictors of diabetes-related outcomes [&lt;span&gt;1-3&lt;/span&gt;]. Even modest dysregulation increases morbidity and mortality, and disadvantaged urban communities such as the Bronx experience disproportionate metabolic disease burden [&lt;span&gt;4, 5&lt;/span&gt;]. The COVID-19 pandemic abruptly disrupted healthcare access, daily routines, and chronic disease management [&lt;span&gt;6, 7&lt;/span&gt;]. Although early reports described short-term increases in BGL and A1c during the initial surge [&lt;span&gt;8-12&lt;/span&gt;], long-term trajectories and whether the pandemic widened existing disparities remain unclear.&lt;/p&gt;&lt;p&gt;This retrospective cohort study was approved by the Einstein–Montefiore Institutional Review Board (protocol #2021-13658). Electronic health records (EHR) from the Montefiore Health System (January 1, 2016–August 17, 2024) were analyzed as previously described [&lt;span&gt;13-27&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Two cohorts were defined based on the presence or absence of type 2 diabetes mellitus (T2DM) as of January 1, 2019. All included patients had at least one recorded encounter before that date. BGL and A1c values were identified using relevant Logical Observation Identifiers Names and Codes; diagnoses used Systematic Nomenclature of Medicine Clinical Terms (see Tables S1 and S2). Monthly averages were computed from January 2019 through July 2024. Analyses were stratified by age, sex, race, ethnicity, insurance coverage, ZIP-code income tertile, and presence of at least one unmet social need.&lt;/p&gt;&lt;p&gt;Patients with T2DM at baseline were older, had lower income, more unmet social needs, and higher comorbidity burden (Table S3). In both the T2DM and non-T2DM cohorts, inpatient and outpatient testing volume declined sharply at the pandemic onset, particularly outpatient testing. Inpatient BGL and A1c values were consistently higher than outpatient values, and patients with T2DM had higher levels than those without (Figure S1).&lt;/p&gt;&lt;p&gt;Both BGL and A1c showed a transient spike in April 2020, returning to baseline shortly thereafter. Long-term levels remained broadly stable, with small downward post-pandemic offsets (Figure 1 and Table S4). Stratified analyses demonstrated similar patterns across demographic and socioeconomic groups. Males had higher glycemic values than females. Among those with T2DM, younger patients had higher BGL and A1c; among those without T2DM, older patients had higher levels. Hispanics, Blacks, and Asians had slightly higher values than Whites. Glycemic markers did not differ across ZIP-code income tertiles, but individuals with unmet social needs had consistently higher levels. Among those with T2DM, Medicaid enrollees had the highest values; among those without T2DM, Medicare enrollees had the highest. Aside from the April 2020 spike, trends across all groups remained stable (Figures S2–S7).&lt;/p&gt;&lt;p&gt;The early-pandemic rise in glycemic indices likely reflects acute illness, stress h","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 2","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12887577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146148628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"November 11–12, 2025, T1DX-QI Learning Session, Journal of Diabetes","authors":"","doi":"10.1111/1753-0407.70182","DOIUrl":"10.1111/1753-0407.70182","url":null,"abstract":"&lt;p&gt;The 2025 Learning Session has been generously sponsored by the Leona M. and Harry B. Helmsley Charitable Trust, Sanofi, Vertex Pharmaceuticals, Dexcom, Medtronic, and Novo Nordisk.&lt;/p&gt;&lt;p&gt;Abstract #1 UndeFEETed: Quality Improvement to Increase Rates of Documented Diabetic Foot Exams for Outpatient Type 2 Diabetes Pediatric Patients3&lt;/p&gt;&lt;p&gt;Abstract #2 Diabetes Autonomy Milestones: Final Report3&lt;/p&gt;&lt;p&gt;Abstract #3 Increasing Access to Dietician Consults: Planning Stages4&lt;/p&gt;&lt;p&gt;Abstract #4 Improving Early CGM Initiation in Pediatric Type 1 Diabetes Through Standardized Education and Documentation Protocols4&lt;/p&gt;&lt;p&gt;Abstract #5 Development of Transition Curriculum from Patient Identified Topics5&lt;/p&gt;&lt;p&gt;Abstract #6 Step by Step: Increasing Physical Activity in Youth with Diabetes5&lt;/p&gt;&lt;p&gt;Abstract #7 Next Stop, Adult Care: Implementing A Transitions Roadmap for Youth with Diabetes6&lt;/p&gt;&lt;p&gt;Abstract #8 Blossoming Outcomes: A Multidisciplinary Model for Youth with Type 1 Diabetes (T1D) and Sub-optimal Glycemic Outcomes7&lt;/p&gt;&lt;p&gt;Abstract #9 Implementing an Early Screening Workflow for Stage 1 and Stage 2 Type 1 Diabetes in a Pediatric Endocrinology Clinic7&lt;/p&gt;&lt;p&gt;Abstract #10 Improving Diabetes Care in a Pediatric Post-Anesthesia Care Unit8&lt;/p&gt;&lt;p&gt;Abstract #11 Improving Diabetic Nephropathy Screening Practices for Type 1 and Type 2 Diabetes8&lt;/p&gt;&lt;p&gt;Abstract #12 Improving Pump Use—Patient Responses9&lt;/p&gt;&lt;p&gt;Abstract #13 Implementation of an Electronic Medical Record Pediatric to Adult Healthcare Transition Planning Tool for Youth with Diabetes Mellitus9&lt;/p&gt;&lt;p&gt;Abstract #14 Improving Clinic Follow-Up for Newly Diagnosed T2DM Patients10&lt;/p&gt;&lt;p&gt;Abstract #15 Increasing the Percentage of Patients on Automated Insulin Delivery Systems within 3 Months of Diagnosis of Type 1 Diabetes11&lt;/p&gt;&lt;p&gt;Abstract #16 Bridging the Gap in CGM Disparities: Standardizing Early CGM Initiation in New-Onset Type 1 Diabetes11&lt;/p&gt;&lt;p&gt;Abstract #17 REACH-AID: Reducing Equity and Access Challenges to Harness Automated Insulin Delivery12&lt;/p&gt;&lt;p&gt;Abstract #18 Improving Transition Readiness Documentation at a Pediatric Diabetes Center13&lt;/p&gt;&lt;p&gt;Abstract #19 Initiating Fear of Hypoglycemia Screening and Education13&lt;/p&gt;&lt;p&gt;Abstract #20 GLP-1 RA Choice and Change Patterns in Pediatric Type 2 Diabetes: A Single Institution Study14&lt;/p&gt;&lt;p&gt;Abstract #21 Validation and implementation of an EHR based DKA risk score14&lt;/p&gt;&lt;p&gt;Abstract #22 Reducing Hospital Readmissions in Youth with High Risk of Diabetic Ketoacidosis15&lt;/p&gt;&lt;p&gt;Abstract #23 Implementation of a Best Practice Advisory to Improve AID Use in Pediatric T1D15&lt;/p&gt;&lt;p&gt;Abstract #24 Improving Food Insecurity Screening and Access to Nutrition Support for Youth with Type 1 Diabetes15&lt;/p&gt;&lt;p&gt;Abstract #25 Improving Screening Rates of Patients at Risk for Type 1 Diabetes in an Academic Institution with Multiple Providers and Clinic Sites16&lt;/p&gt;&lt;p&gt;Abstract #26 Evaluating the Need for Depression and Diabetes Distress Screening in Veterans with Type 1 Diabetes16&lt;/p&gt;&lt;p&gt;Abstract #27","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 S1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70182","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146148659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide","authors":"Julia C. Bernardi,&nbsp;Deivyd V. S. Cavalcante,&nbsp;Ramon Huntermann,&nbsp;Maria E. Molinari,&nbsp;Luana Z. Zanon,&nbsp;Jacinthe Khater,&nbsp;Victor A. Gomez,&nbsp;Caroline O. Fischer-Bacca","doi":"10.1111/1753-0407.70192","DOIUrl":"10.1111/1753-0407.70192","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Pharmacological therapies are recommended for individuals with obesity. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1), and tirzepatide, a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist (GIP/GLP-1), are among the leading pharmacological options for obesity treatment. This network meta-analysis (NMA) aims to evaluate the comparative efficacy of these two agents in reducing body weight and improving glycemic parameters.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Pairwise comparisons within the NMA were conducted using a frequentist approach in RCTs comparing tirzepatide or semaglutide versus placebo, as well as tirzepatide versus semaglutide at their maximum dosages (15 and 2.4 mg, respectively).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 28 RCTs were included, comprising 34 367 participants, 39.6% of whom were women and with a mean age of 57.8 ± 8.95 years. Tirzepatide demonstrated superiority over semaglutide in percentage weight reduction (mean difference [MD] 6.10%; 95% CI: 3.64, 8.57), absolute weight loss (MD 4.55 kg; 95% CI: 1.28, 7.83), BMI reduction (MD 1.71 kg/m²; 95% CI: 0.08, 3.34), and waist circumference reduction (MD 2.89 cm; 95% CI: 1.25, 4.53). Regarding glycemic parameters, tirzepatide was also more effective than semaglutide in reducing HbA1c (MD 0.33%; 95% CI: 0.20, 0.46) and fasting blood glucose (MD 10.39 mg/dL; 95% CI: 4.48, 16.29).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In this NMA, tirzepatide appeared to be superior to semaglutide in both body weight reduction and improvement of glycemic indices.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 2","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12887578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146148640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Algorithm-Based Common Microcirculatory Framework for Monitoring and Visualizing the Integrated Pancreatic Microcirculation in Type 2 Diabetes Mellitus Mice","authors":"Yuan Li,&nbsp;Yingyu Wang,&nbsp;Bing Wang,&nbsp;Weiqi Liu,&nbsp;Mengting Xu,&nbsp;Xiaoyan Zhang,&nbsp;Xueting Liu,&nbsp;Hao Ling,&nbsp;Xu Zhang,&nbsp;Mingming Liu,&nbsp;Ruijuan Xiu","doi":"10.1111/1753-0407.70188","DOIUrl":"10.1111/1753-0407.70188","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Recent research has challenged the viewpoint that pancreatic islets operate independently of surrounding exocrine tissues, revealing a bidirectional blood flow between the endocrine and exocrine pancreas. However, a methodology for simultaneous evaluation of pancreatic microhemodynamics and oxygen profiles remains elusive.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>To generate the common microcirculatory framework, we employed laser Doppler and diffuse reflectance spectroscopy to assess pancreatic microcirculation with concurrent acquisition of microhemodynamic and oxygen data as time-series measurements. The framework's analytical pipeline, featuring outlier adjustment using the boxplot algorithm and comparative normalization strategies (<i>Z</i>-score, min–max, L2, and median scaling), was subsequently validated in a T2DM mouse model with insulin and liraglutide-administered groups. Heat maps and chord plots were used to reveal the integrated dynamics of the associations between microcirculatory blood perfusion and oxygen saturation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The established common microcirculatory framework effectively characterized integrated microhemodynamics and oxygen profiles, with min–max normalizing the microhemodynamic and oxygen. T2DM mice exhibited decreased blood perfusion, reduced red blood cell tissue fraction, diminished oxygen saturation, and lower hemoglobin concentration within the pancreatic microcirculation. Treatment with liraglutide significantly ameliorated these microcirculatory impairments, partially restoring the balance between blood perfusion and oxygen saturation and normalizing the disrupted coherence between oxygenated hemoglobin and speed-resolved blood perfusion.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The common microcirculatory framework provides a novel methodology for monitoring, visualizing, and assessing integrated pancreatic microcirculatory function, with liraglutide demonstrating enhanced efficacy in ameliorating microcirculatory dysfunction in T2DM.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 2","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12869126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146111655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}